Eramet Grande Côte demonstrates the Eramet Group's commitment to responsible mining by achieving IRMA 50 performance level Paris, February 5th, 2026, 08:30 a.m. PRESS RELEASE Eramet Grande Côte demonstrates the Eramet Group's commitment to responsible mining by achieving IRMA 50 performance level Eramet Grande Côte, Eramet Group’s first site audited according to the IRMA standard, a global benchmark for responsible mining.First site audited according to the IRMA standard in Senegal, and the first mineral sands site to achieve this level globally.Eramet Grande Côte is now among the 14 mi...
Eramet Grande Côte illustre l’engagement du Groupe Eramet en faveur d’une exploitation minière responsable en atteignant le niveau de performance IRMA 50 Paris, le 5 février 2026 à 8h30 COMMUNIQUE DE PRESSE Eramet Grande Côte illustre l’engagement du Groupe Eramet en faveur d’une exploitation minière responsable en atteignant le niveau de performance IRMA 50 Eramet Grande Côte, premier site du Groupe Eramet audité selon le standard IRMA, référence mondiale de l’exploitation minière responsable.Premier site audité selon le standard IRMA au Sénégal, et premier site de sables minéralisés au...
While we do not deny the uncertainties and risks associated with artificial intelligence (pricing pressures, organisational change, etc.), we remain constructive on this issue, given the significant volume opportunities in prospect for the sector with the integration of agentic AI. Moreover, improving growth momentum in 2026 should reduce pressure on sector valuations (discount >30% vs Stoxx 600 vs a premium of 10% four years ago). On this basis, we have upgraded Bechtle (Outperform vs Neutral),...
Sans nier les incertitudes et risques liés à l’IA (pressions tarifaires, changements organisationnels, etc.), nous restons constructifs sur cette thématique tant les opportunités de volumes autour de l’intégration de l’IA agentique sont importantes pour le secteur. D’autant plus que l’amélioration de la dynamique de croissance en 2026 devrait permettre de réduire la pression sur les valorisations du secteur (décote >30% vs Stoxx 600 contre une prime de 10% il y a 4 ans). Dans ce contexte, nous r...
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...
Eramet: Announcement from the Board of Directors regarding the management of the Group Paris, February 1st, 2026, 22:45pm PRESS RELEASE Eramet: Announcement from the Board of Directors regarding the management of the Group The Board of Directors of Eramet, meeting on Sunday, February 1st, has decided to terminate the mandate of Mr. Paulo Castellari as Chief Executive Officer, due to divergences on operating methods. The termination of his mandate as Chief Executive Officer takes effect this evening. The Board of Directors has appointed its Chairwoman, Ms. Christel Bories, as Chief Exe...
Eramet : Annonce du Conseil d’administration relative à sa Direction Générale Paris, le 1er février 2026, 22h45 COMMUNIQUÉ DE PRESSE Eramet : Annonce du Conseil d’administration relative à sa Direction Générale Le Conseil d’administration d’Eramet, réuni dimanche 1er février, a décidé de mettre un terme au mandat de son Directeur général, Monsieur Paulo Castellari, en raison de divergences avec ce dernier sur les modes de fonctionnement. Son mandat de Directeur général de l’entreprise prend fin ce soir. Le Conseil d’administration a nommé ce jour sa Présidente, Madame Christe...
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.